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Edited by Ivan SadowskiAbstract SOX6 plays key functions in several developmental
processes, including neurogenesis and skeleton formation. In this
report, we show that SOX6 is modiﬁed in vitro and in vivo by
small ubiquitin-related modiﬁer (SUMO) on two distinct sites.
Mutation of both sites abolished SOX6 sumoylation and in-
creased SOX6 transcriptional activity. SUMO dependent
repression of SOX6 transcription was promoted by UBC9
whereas siRNA to UBC9, cotransfection of inactive UBC9 or
a SUMO protease increased SOX6 transcriptional activity. Fur-
thermore, co-expression of SOX6 with SUMO2 results in the
appearance of SOX6 in a punctate nuclear pattern that colocal-
ized with promyelocytic leukemia protein, which was partially
abolished by mutations in SOX6 sumoylation sites.
 2006 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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Recently, several ubiquitin-like proteins that act as posttrans-
lational modiﬁcators of other proteins have been identiﬁed.
Small ubiquitin-related modiﬁer (SUMO) proteins are mem-
bers of this family that have been shown to regulate diverse cel-
lular functions of a variety of target proteins [1–4]. SUMO
proteins are conjugated on the lysine residue in the consensus
sequence wKxE (where w represents a hydrophobic amino acid,
and x is any amino acid). The mechanism involves a multiple-
step cascade. SUMO conjugation requires a heterodimeric
E1-activating enzyme and a single E2-conjugating enzyme,
UBC9 [1–4]. Although in the ubiquitin pathway, at least one
additional factor called E3 ubiquitin ligase is needed for sub-
strate recognition and ubiquitin addition at the target protein,
this E3 protein ligase does not appear to be required for SUMO
conjugation in vitro. However, such E3 ligases play important
roles in modulating the eﬃciency of SUMO attachment to
target proteins. Three types of SUMO E3 ligases have been
described: proteins of the PIAS family, RanBP2 and Pc2 [2].Abbreviations: BMPs, bone morphogenetic proteins; Col2a1, type-II
collagen alpha1 chain; PML, promyelocytic leukemia protein
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doi:10.1016/j.febslet.2006.01.031Many of the functionally diverse proteins identiﬁed as
SUMO targets are involved in control of gene expression
and include transcription factors, co-activators and co-repres-
sors or components of large sub-nuclear structures called pro-
myelocytic leukemia protein (PML) nuclear bodies [1,4].
SUMO modiﬁcation often represses transcriptional activity
by direct sumoylation of a transcriptional factor, a co-activa-
tor, and/or increased recruitment of co-repressors. Other ef-
fects on transcription are mediated by PML nuclear bodies
which, through sumoylation, control the binding/release of
components of the transcriptional machinery [5].
The Sox family of transcription factors are involved in
embryonic development as regulators of cellular determination
and diﬀerentiation [6,7]. SOX6 has been shown to play a key
role in the development of the central nervous system, chon-
drogenesis and cardiac and skeletal muscle cell maintenance
[8–10]. Some cytokines are able to control Sox6 expression,
such as BMP-2 during chondrogenesis [11]. In addition,
SOX6, L-SOX5 and SOX9 physically interact and functionally
cooperate in the activation of the type-II collagen alpha1 chain
(Col2a1) [8], whereas SOX6 represses the Fgf3 promoter
through interaction with the co-repressor CtBP2 [12]. In this
study we show that SOX6 is sumoylated in vivo and in vitro.
Moreover, we ﬁnd that sumoylation of SOX6 inhibits its tran-
scriptional activity and its functional synergism with SOX9 on
type-II collagen enhancer. Based on these observations, we
suggest a potential role of SUMO in regulating SOX6-depen-
dent transcriptional activity.2. Materials and methods
2.1. Plasmids constructs and antibodies
pCDNA3-SOX6His was a gift from Dr. de Crombrugghe, and was
used as to create the sumoylation mutants (K364R, K377R and the dou-
ble mutant) using PCR approaches. pCDNA3-SOX9HA was a gift
from Dr. Harley. Col2a1 enhancer reporter construct and SUMO1, 2
and 3, SENP2, hUBC9 and hUBC9 (C93S) and pIRESCFP-SUMO2
expression vectors as well as GST fusion proteins were previously de-
scribed [11,13,14]. SOX6 antibodies were produced in rabbits as previ-
ously described [11]. Anti-hUBC9 was raised against the hUBC9
peptide (CEYEKRVRAQAKKFAPS). Antibodies against HA-pep-
tide (Roche) and a-tubulin (Sigma) and SUMO2 (Zymed) were used
for immunoblotting.
2.2. Transient transfection
HEK-293 T, HeLa, C2C12 and COS-7 cells were transfected with
FuGENE 6 (Roche Diagnostics) or Lipofectaminee (Invitrogen),
C3H10T1/2 cells were transfected with Lipofectamine 2000 (Invitro-
gen).blished by Elsevier B.V. All rights reserved.
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Two micrograms of total RNA, isolated using the Ultraspece RNA
Isolation System (Biotecx), were reverse-transcribed using a Ready-to-
Go First Strand Kit (Amersham). Quantitative PCRs were carried out
on 96-well plates using Applied Biosystem’s ABI Prism 7000 and Taq-
man 5 0-nuclease probe method (Applied Biosystems). All transcript
levels were normalized to that of GAPDH and transfection eﬃciency
assessed by GFP expression.
2.4. Luciferase assays
Luciferase activities of transfected HEK-293 T cells were quantiﬁed
as previously described [11].
2.5. SUMO conjugation assays in vitro and in vivo
SUMO conjugation assays in vitro and in vivo sumoylation assays
were performed as previously described [13,14].
2.6. Immunoﬂuorescence assays
HeLa and C2C12 cells were seeded onto Costar 35-mm 6-well plates
containing 12-mm-coverslips. 48 h after transfection cells were ﬁxed in
4% paraformaldehyde for 20 min, permeabilised in 0.1% Triton X-100
and blocked with 3% BSA in PBS. Cells were stained for SOX6 with
rabbit anti-SOX6 at 1:200 dilution or mouse anti-His (Roche) at
1:200, followed for goat anti-rabbit or anti-mouse, respectively, IgG
conjugated with Alexa 568, at 1:2000 (Molecular probes), and for
PML with rabbit anti-PML at 1:200, followed by goat anti-rabbit
IgG conjugated with Alexa 488, at 1:2000. The presence of SOX6,
pECFP-SUMO2, and PML was detected using a Leica TCS SL in-
verted laser scanning confocal microscope.N
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Fig. 1. SOX6 is sumoylated in vitro. (A) Schematic representation of prot
conserved between human, mouse and rat sequences. (B) 35S-labeled SOX6 a
mix containing recombinant E1 (SAE1/SAE2), UBC9 and SUMO1, 2 or 3 a
with the indicated amounts of UBC9.2.7. RNA interference experiments
HEK-293-T cells were transfected with the corresponding constructs
and 200 pmol of UBC9 or unrelated (mouse Id1) siRNA oligonucleo-
tides with Lipofectamine 2000. 24 h later, luciferase assays were done
and UBC9 expression was analyzed by immunoblotting.3. Results
3.1. SOX6 is sumoylated in vitro and in vivo
Inspection of the SOX6 sequence indicated two sequences
(IK364NE and VK377DE) of the motif wKxE required for
modiﬁcation by SUMO (Fig. 1A). We thus examined the
possibility of covalent modiﬁcation of SOX6 by SUMO. In
vitro sumoylation assays revealed multiple forms of SOX6
conjugated to SUMO1/-2/ or -3 (Fig. 1B). To determine
the requirement for UBC9 in SOX6 sumoylation, UBC9
was titrated into an in vitro sumoylation assay. Increasing
amounts of recombinant UBC9 brought a dose dependent in-
crease in SUMO modiﬁcation of SOX6 (Fig. 1C). We also
tested whether the known E3 ligases, RanBP2 or proteins
of the PIAS family, enhanced sumoylation of SOX6 at sub-
maximal amounts of UBC9 (12 ng). In these conditions, we
could not detect a signiﬁcant stimulation of SOX6 sumoyla-
tion by either RanBP2, PIAS1, PIASxa or PIASxb (data not
shown).C
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quired for SOX6 sumoylation, these motifs (IK364NE and
VK377DE) were targeted for site-directed mutagenesis. Single
mutants and the double mutant were tested for in vitro sumoy-
lation. Whereas both single mutants were still sumoylated, the
double mutant showed much lower formation of SOX6–
SUMO complexes (Fig. 2A).
We also analyzed whether this SUMO modiﬁcation occurs
also in COS-7 cells. Immunoblots showed two high molecular
weight bands corresponding to sumoylated forms of SOX6
suggesting that a fraction of SOX6 undergoes covalent modiﬁ-- - - - - - - - -
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Fig. 2. Sites of SOX6 sumoylation in vitro and in vivo. (A) 35S-labeled PML
and sumoylated products were visualized by SDS–PAGE. (B) COS-7 cells
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with antibody against SOX6.cation when co-expressed together with SUMO1, 2 or 3. More-
over, these bands were reduced when the K364R and K377R
mutants where expressed and absent when the double mutant
form of SOX6 was transfected (Fig. 2B).
3.2. Sumoylation inhibits SOX6 transcriptional activity
In view of our ﬁndings that SOX6 is sumoylated and that
sumoylation did not signiﬁcantly alter SOX6 protein stability
(Supplementary Fig. 1), their functional signiﬁcance was stud-
ied in the context of transcriptional activation. Transcriptional
assays were performed using a chondrocyte-speciﬁc Col2a1+  - - - - +   - - SOX6 K377R
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responsive [11]. We observed that co-expression of increasing
amounts of UBC9 increased sumoylation of SOX6 (Fig. 3A)
and gradually reduced SOX6-mediated transcription in HEK
293 T cells (Fig. 3B). In contrast, co-expression of either
increasing amounts of a UBC9 dominant negative or a SUMO
speciﬁc protease (SENP2), which decreased sumoylation of
SOX6 (Fig. 3A), increased the reporter gene expression
(Fig. 3B).
Next, we determined the transcriptional activity of wild type
and sumoylation mutants of SOX6 in HEK 293 T cells.
Whereas SOX6 single mutants displayed only slightly higherHisSOX6 - +    +    +  +    +    +
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Fig. 3. Sumoylation represses SOX6 transcriptional activity. (A) SOX6 prote
above. (B) HEK-293 T cells were transfected with the Col2a1-enhancer rep
indicated expression vectors (0.05, 0.2 and 1 lg). Luciferase activities rep
normalization by b-galactosidase. (C, D) HEK 293-T cells were transfected
luciferase activity measured as above indicated.reporter responses, SOX6 double mutant enhanced about
50% the transcriptional activity of SOX6 wild type (Fig. 3C).
Moreover, SOX6 double mutant became partially refractory
to the inhibitory transcriptional eﬀects of overexpression of
UBC9 or activation by UBC9 DN (Fig. 3D). These results
indicate that SUMO modiﬁcation exerts a repressive eﬀect
on SOX6-dependent transactivation.
3.3. SUMO represses SOX6/SOX9 synergism
SOX6 and SOX9 have been shown to functionally cooper-
ate in the activation of the Col2a1 [8]. As previously de-
scribed, cotransfection of SOX6 induced a 2-fold increaseUBC9             UBC9DN     SUMO protease
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ingly, in HEK 293 T cells, cotransfection of SOX6 double
mutant induced a further 2-fold activation compared to wild
type SOX6 (Fig. 4A). Similar to the data from transfection of
SOX6 alone, UBC9 inhibited and UBC9 DN activated tran-
scriptional activity of wild type SOX6 whereas SOX9 alone
and SOX6 double mutant became refractory to these eﬀects
(Fig. 4A). We also analyzed the eﬀects of mutation of
SOX6 on endogenous Col2a1 mRNA expression. Although
C3H10T1/2 cells express Col2a1 at low levels, following tran-
sient transfection of SOX9 and SOX6 plasmids, Col2a1
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mRNA, transfection with either SOX6 double mutant or
cotransfection of UBC9 DN induced 2-fold increase in
Col2a1 mRNA levels (Fig. 4B). To further conﬁrm that
sumoylation of SOX6 at these sites mediates their eﬀects on
transcription we ablated UBC9 expression with siRNA and
measured SOX6/SOX9 eﬀects to Col2a1 enhancer in HEK
293 T cells. siRNA directed against UBC9 mRNA, which sig-
niﬁcantly reduced endogenous UBC9 expression and blocked
SOX6 sumoylation (Fig. 4C), enhanced the SOX6 eﬀects on
Col2a1 enhancer whereas had much lower eﬀects on the ef-
fects of the SOX6 double mutant (Fig. 4D).- -
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Fig. 5. Sub-cellular localization of SOX6 in a SUMO-dependent manner. (A) HeLa cells were transfected with SOX6 and CFP-SUMO. Cells were
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SOX6
Various studies have reported that SUMO conjugation can
alter the subcellular localization of the modiﬁed protein [5].
Immunoﬂuorescence analysis in HeLa cells showed that after
co-expression with SUMO2, SOX6 was distributed in punc-
tate nuclear structures reminiscent of nuclear bodies
(Fig. 5A). We conﬁrmed that the nuclear punctate structures
where SOX6 is localized completely overlapped with anti-
PML staining. Furthermore, whereas SOX6 co-expressed with
SUMO2 in C2C12 cells was localized in punctate nuclear
structures, co-expression of SUMO2 with the SOX6 double
sumoylation mutant resulted in a signiﬁcant loss of the punc-
tate staining pattern of SOX6 (Fig. 5B). Altogether, these re-
sults indicate that, although sumoylation is not required for
SOX6 nuclear localization, SUMO proteins inﬂuence SOX6
sub-nuclear distribution.4. Discussion
Sumoylation of transcription factors has been reported to
have a range of diﬀerent eﬀects on their activity. For instance,SUMO modiﬁcation of Tcf-4 [15] or the heat shock factors
HSF1 [16] has been shown to increase their transactivation
capacity. However, it is becoming clear that in the vast major-
ity of the cases described to date, conjugation of SUMO re-
presses the activity of transcriptional activators [1–4]. In this
report, we show that sumoylation of SOX6 has a repressive ef-
fect on transcriptional activation. Data from the SOX6 sumoy-
lation mutants further support that the transcriptional eﬀects
seen by modulating UBC9 activity, at least partially, rely on
direct eﬀects of sumoylated SOX6 in transcriptional com-
plexes. For instance, the double mutant is partially refractory
to the eﬀects of either overexpression of UBC9 or ‘‘knocking
down’’ endogenous UBC9 expression. In addition, the SOX6
double mutant has stronger ability to activate the chondro-
cyte-speciﬁc Col2a1 enhancer as well as to increase transcrip-
tion of endogenous Col2a1 mRNA.
Interestingly, it was found that not only SOX6, but also
SOX9 is sumoylated, and these sumoylation sites occur within
synergy control motif (SC) of SOX9 [17]. The SC protein motif
was identiﬁed in transcription factors that activate transcrip-
tion synergistically when their binding sites are present in mul-
tiple copies in the promoter region, which is the case of the
Col2a1 enhancer [18]. This could be also the case of SOX6
R. Ferna´ndez-Lloris et al. / FEBS Letters 580 (2006) 1215–1221 1221since both sumoylation sites are included in two tandem re-
peated SC motifs and synergism of SOX6/SOX9 on the Col2a1
enhancer is profoundly aﬀected by sumoylation of SOX6 at
these sites.
In most sumoylated transcription factors the sumoylation
site lies within a negative regulatory region [18,19]. Further-
more, recruitment of SUMO to a promoter, in the context of
Gal4-SUMO fusion, is suﬃcient for repression, suggesting that
SUMO itself can directly bind transcriptional co-repressors
[20]. Interestingly, SOX6, which mainly function as transcrip-
tional activator, has been shown to have repressive eﬀects on
the Fgf-3 promoter through interaction with the co-repressor
CtBP2. Interaction between SOX6 and CtBP2 takes place in
a short sequence located next to the SOX6 sumoylation sites
[12]. Although we could also conﬁrm interaction between
CtBP2 and SOX6, this interaction was independent of the
SOX6 sumoylation state (data not shown).
Many SUMO-modiﬁed proteins have been found in PML
nuclear bodies [1–4]. Mutation of the SUMO acceptor sites
in PML induces nuclear body components such as Sp100
and CBP to relocalize in the nucleus [21]. Similarly, SUMO
modiﬁcation of certain proteins like p53 or Sp100 correlates
with their partition to sub-nuclear domains such as PML
bodies [21,22]. This is also the case of SOX6 since the mutant
lacking both sumoylation sites shows a partially impaired
recruitment to PML nuclear bodies. It has been proposed that
PML-NBs may play a speciﬁc, though indirect, role in tran-
scription by sequestration and/or modiﬁcation of transcription
factors [1–4].
Thus, three possible separate, but non-mutually exclusive,
mechanisms of SUMO mediated repression of SOX6 can be
envisioned. Directly, through disruption of the transcriptional
activation complex with SOX9 or by recruitment of co-repres-
sor to the sumoylated complex and/or indirectly, by sequestra-
tion of SOX6 to PML bodies, thus removing it from
transcriptionally active sites. As the role of SUMO in the
chondrocytic diﬀerentiation program has not been previously
addressed, the identiﬁcation of SOX6 as a substrate for SUMO
modiﬁcation, suggest the possibility that sumoylation may be
relevant for regulation of chondrocyte diﬀerentiation.
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